- MicuRx showcased the latest research progress on their pipeline
products, MRX-5 and MRX-8, at the 7th World
Bronchiectasis Conference
- Three significant study results further support the potential
of MRX-5 and MRX-8 in treating Nontuberculous Mycobacteria
(NTM) lung disease and Pseudomonas aeruginosa
infections
DUNDEE,
Scotland, July 18, 2024 /PRNewswire/ --
Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx",688373.SH)
presented the latest research progress on their novel antibiotic
pipeline products, MRX-5 and MRX-8, at the 7th World Bronchiectasis
Conference (WBC) held in Dundee,
Scotland, from July 4 to 6,
2024. These research results provide new hope for the future
treatment of Nontuberculous Mycobacteria (NTM) lung disease and
Pseudomonas aeruginosa infections.
Conference Background
The World Bronchiectasis Conference is a leading global academic
conference focused on the research and treatment of bronchiectasis.
This conference brings together top scientists and clinical experts
from around the world to discuss the latest research developments,
clinical management strategies, and the development of new
therapies for bronchiectasis.
Research Highlights
As a biopharmaceutical company dedicated to developing
innovative anti-infective drugs, MicuRx presented three
significant research results in poster presentation at the
conference. These studies further support the potential of MRX-5
and MRX-8 in the treatment of specific infections:
- In Vitro and In Vivo Activity of A Novel Leucyl-tRNA
Synthetase Inhibitor Against Mycobacterium Abscessus
The active drug MRX-6038 was very potent against M.
abscessus clinical isolates in vitro with MIC90 0.5
mg/L while the control drug clarithromycin MIC90 was 4
mg/L. MRX-6038 greatly reduced the resistance frequency of standard
of care drugs (Ethambutol, Clarithromycin, Rifabutin, Clofazimine,
Amikacin, Imipenem, Ciprofloxacin) by more than 10 to 100,000
folds, demonstrating the potential for combination with the
background therapy. Oral prodrug MRX-5 was tested in mice with lung
infections due to M. abscessus isolates, and efficacy was
demonstrated against infections with both clarithromycin-sensitive
and clarithromycin non-susceptible isolates.
- In Vitro Activity of Novel Leucyl-tRNA Synthetase
Inhibitor Against Mycobacterium Avium Complex
MRX-6038, the major activedrug of MRX-5, has demonstrated potent
in vitro activity against Mycobacterium avium clinical
isolates including isolates not susceptible to clarithromycin. When
MRX-6038 was combined with Clarithromycin, Rifabutin, Amikacin, and
Ethambutol, the resistance frequency of these standard of care
drugs was greatly reduced to below 6.5×10-11. Further
studies are warranted for the evaluation of MRX-6038 for the
treatment of Mycobacterium avium pulmonary disease.
- In Vitro and In Vivo Activity of A Novel Antibiotic In The
Polymyxin Class Against Pseudomonas Aeruginosa
MRX-8 demonstrated potent in vitro activity against P.
aeruginosa including tobramycin and amikacin resistant clinical
isolates. In mouse models with P. aeruginosa lung infections
of both tobramycin-sensitive and tobramycin-resistant isolates,
nebulized MRX-8 treatment significantly decreased bacterial load in
the lung tissues, demonstrating bactericidal activity.
About MRX-8
MRX-8 is a novel polymyxin antibiotic developed by MicuRx,
primarily used to treat severe infections caused by
multidrug-resistant Gram-negative bacteria. Traditional polymyxins
are limited in clinical use due to nephrotoxicity and
neurotoxicity. Through meticulous structural design, MRX-8 not only
maintains or enhances therapeutic efficacy but also significantly
improves safety by reducing these potential toxic risks.
In 2022, MRX-8 completed Phase I clinical trials in the United States. In 2023, it completed Phase
I enrollment in China, with
primary study results released in June
2024. These trial results indicated that MRX-8 achieved the
desired therapeutic levels in the human body at the expected
clinical doses for infections caused by Escherichia coli,
Pseudomonas aeruginosa, and Acinetobacter
baumannii.
Besides systemic administration, the company plans to explore
the development of an inhaled formulation of MRX-8 to uncover its
clinical and commercial value in targeted treatment of chronic lung
infections.
About MRX-5 and NTM
MRX-5 is a novel benzoxaborole antibiotic developed by MicuRx
for infections caused by NTM.
NTM is a common pathogen causing bronchiectasis. In recent
years, the incidence of NTM diseases has rapidly increased,
becoming a significant public health issue.
[1] Among diseases caused by NTM,
Mycobacterium avium complex and Mycobacterium
abscessus complex account for 70%-95% of NTM diseases.
[2] The main clinical symptoms of NTM
pulmonary infections include persistent cough, sputum production,
chest pain, shortness of breath, fatigue, weight loss, and malaise.
[1]
Preclinical data indicates that MRX-5 has good antibacterial
activity against most common NTM pathogens and has demonstrated
good safety in animal studies. Additionally, its characteristics of
minimal drug interactions, low resistance potential, and oral
availability make it an ideal candidate for the treatment of
chronic infections. Currently, MRX-5 is undergoing Phase I clinical
trials, offering a promising new treatment option for patients with
NTM diseases.
About Shanghai MicuRx Pharmaceutical Co., Ltd.
MicuRx is a biopharmaceutical company focusing on novel
therapeutics for infectious diseases. With global independent
intellectual property and competitiveness, we are committed to the
discovery, development, and commercialization of innovative drugs
for unmet medical needs. Since the company was founded in 2007,
MicuRx has adhered to the principle of "Better therapy through
superior medicine", focusing on the increasingly serious problem of
global antimicrobial resistance.
For more information, please visit our website at
www.micurx.com
References:
[1] Chinese
Medical Association Tuberculosis Branch. Guidelines for the
Diagnosis and Treatment of Nontuberculous Mycobacterial Diseases
(2020 Edition). Chinese Journal of Tuberculosis and Respiratory
Diseases, 2020, 43(11): 918-946. DOI:
10.3760/cma.j.cn112147-20200508-00570.
|
[2] Luo Kuo,
Chen Shanze, Chen Rongchang, et al. Host Factors of Nontuberculous
Mycobacterial Diseases. Chinese Journal of Tuberculosis and
Respiratory Diseases, 2022, 45(7): 716-720. DOI:
10.3760/cma.j.cn112147-20211210-00872.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/micurx-presents-innovative-antibiotic-research-results-at-the-7th-world-bronchiectasis-conference-302200284.html
SOURCE MicuRx Pharmaceutical